AzTrials
AzTrials

HealthyReverse-DMNCT05512871

A Mobile Health-enabled Lifestyle Intervention Among Women With History of Gestational Diabetes(GDM)

A study testing Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM) in people with Healthy and Gestational Diabetes Mellitus in Pregnancy, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study aims to explore: (1) the relationship between lifestyle factors (eating, movement behaviour, sleep and stress) and glycaemic profile, and (2) the feasibility of delivering lifestyle intervention through the proposed mHealth strategy. Read more about this study

Who is it for?
Ages 21 to 45 years, women onlyHealthy volunteers can take part
What is being tested?
Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
61 participants
Where
1 siteSingapore
Study dates
19 Sep 2022to 28 Apr 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy female volunteers (age 21-45 years)
  • A history of GDM in the past 5 years
  • Not planning to conceive during the study period
  • Not performing full breastfeeding during the study period
  • Own a smart phone(mobile phone) compatible with study App (Android v10 and above)
  • Proficient in English language
Show all 9Show fewer
  • Plan to stay in Singapore for the next 1 year
  • Willing to comply to study protocol
  • Able to provide a written informed consent

Who cannot join

  • Current and/or previous diagnosis of diabetes except GDM
  • Currently pregnant
  • Given birth within last 12 weeks
  • Following special diet or dietary restriction
  • Experiencing severely limited mobility (e.g. wheelchair bound, need walking aid etc.)
  • Diagnosed with malnutrition, eating disorder, severe insomnia
Show all 10Show fewer
  • Diagnosed with cancers, unstable heart related diseases, severe kidney disease
  • Diagnosed with severe unstable mental conditions, dementia or cognitive impairment
  • Alcohol or drug abuse
  • Medications known to influence glucose metabolism e.g. peroral corticosteroids

Trial locations and contacts

1 site in 1 country.

Singapore1 site
  • Human Development Research Centre (Hdrc)

    Singapore, 117597

Other trials in Singapore

About this study

Official title: A Mobile Health (mHealth)-Enabled Lifestyle Intervention Among Women With History of Gestational Diabetes (GDM): a Pilot Randomized Controlled Trial

This study aims to explore: (1) the relationship between lifestyle factors (eating, movement behaviour, sleep and stress) and glycaemic profile, and (2) the feasibility of delivering lifestyle intervention through the proposed mHealth strategy.

Read the detailed description

A 2-week observational period, followed by a 8-week parallel 2-arm, single-centre, randomized controlled trial (RCT) study involving 60-80 multi-ethnic healthy women (Chinese, Malay, Indian, others) subjects aged between 21 and 45 years who had a previous diagnosis of Gestational diabetes mellitus (GDM).

Type 2 diabetes is the most common type of diabetes and if left untreated or is ill-managed, can lead to detrimental long-term health problems such as heart disease, kidney disease and stroke. Type 2 diabetes is often related to lifestyle and develops over time; with proper interventions, it could be avoided in some cases. GDM stands for Gestational Diabetes Mellitus and can occur in some pregnant women, usually from week 24 of pregnancy. Women with a history of GDM have also been connected to a lifetime risk of developing type 2 diabetes and cardiovascular disease. In Singapore, it is estimated that 4 in 10 women with GDM could develop pre-diabetes or diabetes within five years of their pregnancy. Therefore, postpartum follow-up is essential in early detection of, preventing or delaying the development of Type 2 diabetes in this group.

The study hypothesize that there is an association between glycaemic profile and daily lifestyle (i.e. eating behavior, physical activity sleep and stress) among women with a history of GDM. The study also hypothesize that it is feasible to adopt a holistic approach and introduce a personalized mHealth intervention to promote metabolic and mental health among women with a history of GDM. The study is a parallel 2-arm, single-centre randomized controlled trial based on 1:1 allocation ratio.

The study arms are; Group 1 (Intervention group) and Group 2 (Control group). The study will begin with baseline data collection (anthropometric measures, body composition, biochemistry tests, questionnaires) and 14-day observation of interstitial glucose and lifestyle (diet, physical activity, sleep and stress). Every subject, irrespective of their group allocation, will use Oura ring and Oura App throughout the study duration. Every subject randomized to Group 1( Intervention group) will additionally receive HealthifySG App which provides personalized lifestyle interventions that last for 4 weeks. Lifestyle recommendations (targeting diet, physical activity, sleep and stress) will be delivered by study team member through the HealthifySG App on a weekly basis. On the contrary, subjects randomized to Group 2 (Control group) will not receive the HealthifySGApp and lifestyle interventions during this period. Subsequently, both groups will be followed-up for 4 weeks.

The overall aim of the REVERSE DIABETES programme is three pronged: (1) to be more proactive in screening to identify women with a history of GDM in polyclinics and the community, (2) to explore the potential of mobile health (mHealth) strategies to engage these women and deliver holistic and personalized interventions for promoting metabolic health and mental wellbeing, and (3) to engage primary care physicians to use mHealth if proven acceptable and useful in the long term follow up of these GDM women in the polyclinics and communities. We hope to optimize the preventive measures within the community in the long term.

Based on the above considerations, conducting a pilot randomized controlled trial would allow the study team to: (1) better understand the women's lifestyle behaviours and preferences, (2) validate the devices used for measuring lifestyle behaviours, (3) examine the feasibility of the proposed mHealth intervention and personalized lifestyle recommendation, (4) evaluate the initial effects and cost-effectiveness of the intervention, and (5) identify other benefits and potential risk of the proposed idea.

Being tested
Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)
Keywords
Healthy women, Gestational Diabetes Mellitus history, GDM history, mobile health apps
Medical subject headings
Diabetes, Gestational

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)Behavioural

    The study aim to conduct lifestyle intervention trials to examine the feasibility, efficacy, and cost-effectiveness of the mHealth approach in preventing them from developing Type 2 Diabetes in the future. This pilot study will primarily aim to determine the feasibility of our intervention approaches as well as enhance health literacy and promote healthy lifestyle in the study participants. In the longer term, we hope that the proposed mHealth intervention can be translated to include women from the community setting and involve wider healthcare setting to come together and reduce the burden of Type 2 Diabetes in Singapore.

Study groups in NCT05512871
Study groupRoleWhat they receive
Group 1 (Intervention group)ExperimentalGroup 1 (Intervention group) :Oura ring with Oura App + HealthifySG App (receive lifestyle interventions via HealthifySG App)
Receives: Behavioral: Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)
Group 2 (Control group)OtherGroup 2 (Control group) : Oura ring with Oura App alone (without lifestyle interventions)
Receives: Behavioral: Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mobile health application feasibility

    Number of participants that show a change in lifestyle behaviour through the mobile health application usage.

    Measured: 10 weeks

Secondary outcomes (8)
  1. Oral glucose tolerance test (OGTT) measurements

    Glucose metabolism is measured during baseline visit via a fasting blood test and endpoint visit via the Oral glucose tolerance test (OGTT) blood test. The difference in the blood glucose profile between the baseline and the endpoint visit will determine the effects of the proposed mobile Health intervention.

    Measured: Week -1 and 10

  2. Change in sleep quality as assessed by the Oura Ring Sleep Score.

    Participants will be issued a wearable device (Oura ring) to capture durations of deep sleep, rapid eye movement (REM) sleep, light sleep and nightly heart rate. Sleep Score ranges from 0-100, where a higher score reflects better sleep outcome.

    Measured: 10 weeks

  3. Change in daily physical activity levels as assessed by the Oura Ring Activity Score.

    Participants will be issues a wearable device (Oura ring) to capture durations of activity, inactivity and rest. Activity score ranges from 0-100, where a higher score reflects better balance between activity and rest.

    Measured: 10 weeks

  4. Postprandial glucose

    Glucose measurements taken using the Continuous Glucose Monitoring System.

    Measured: 14 days

  5. Change in quality of life

    Assessed by the 36-item short form survey (SF-36)

    Measured: Week -1 and 10

  6. Change in anxiety (if any)

    Assessed by State-Trait Anxiety Inventory (STAI)

    Measured: Week -1 and 10

  7. Change in depression (if any)

    Assessed by Beck Depression Inventory-II (BDI-II).

    Measured: Week -1 and 10

  8. Change in intake of meals

    Assessed by Electronic diary(E-Diary) by recording the pictures of food items for meals

    Measured: 14 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2022
  2. Study start19 Sep 2022
  3. Primary completion28 Apr 2023
  4. Study completion28 Apr 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study is a parallel 2-arm, single-centre randomized controlled trial based on 1:1 allocation ratio: Group1 (Intervention group) - Oura ring with Oura App + HealthifySG App (receive lifestyle interventions via HealthifySG App) Group 2 (Control group) - Oura ring with Oura App alone (without lifestyle interventions)
Masking
None (open label)
Enrolment
61 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05512871
Sponsor's protocol ID
2021/00843
Acronym
Reverse-DM
Status last verified
Nov 2023
First submitted
25 Jul 2022
Last updated
8 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Liew SJ, Soon CS, Chooi YC, Tint MT, Eriksson JG. A holistic approach to preventing type 2 diabetes in Asian women with a history of gestational diabetes mellitus: a feasibility study and pilot randomized controlled trial. Front Clin Diabetes Healthc. 2023 Sep 28;4:1251411. doi: 10.3389/fcdhc.2023.1251411. eCollection 2023.

    PubMed 37841647

Questions about this trial

What is this clinical trial studying?

A study testing Personalized mHealth intervention to promote short-term metabolic and mental health among women with a history of Gestational Diabetes Mellitus (GDM) in people with Healthy and Gestational Diabetes Mellitus in Pregnancy, run by Institute for Human Development and Potential (IHDP), Singapore at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mobile health application feasibility (time frame: 10 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05512871, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in